Dyadic Announces Commercial Agreement with Opes Diagnostics for Serum-Free Cell Culture Media

Dyadic Applied BioSolutions has entered into a commercial agreement with Opes Diagnostics to support the launch of its recombinant human and bovine transferrin, human and bovine FGF products for use in serum-free cell culture media applications. Opes will leverage its commercial relationships to identify and engage potential customers in Europe, Israel, and Asia, while Dyadic retains the ability to sell directly and work with additional partners globally.